Medtronic CEO expects to submit renal denervation data to FDA this year, overcoming previous failures

Daily, Dublin, Events, Geoff Martha, J.P. Morgan Healthcare Conference, JPM week, Medical Devices, Medtronic, News, renal denervation, SYN, Top Story / January 12, 2021

Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.